Goldentree Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Goldentree Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-70,415	Closed	-$5.43M	–	30
2017 Q2	$5.43M	Sell	70,415 -98,835	-58%	-$7.01M	1.23%	20
2017 Q1	$11.7M	Sell	169,250 -80,750	-32%	-$5.42M	4.46%	9
2016 Q4	$14.8M	Buy	+250,000	New	+$15.4M	1.84%	15

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Goldentree Asset Management's XBI Position: Q3 2017 in Review

Goldentree Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2017, closing a stake of 70,415 shares — an estimated $5.43M sold.

Goldentree Asset Management first reported a position in XBI in Q4 2016 and held it in 3 quarters. The position peaked at $14.8M in Q4 2016. 349 funds tracked by Wall St. Rank hold XBI as of Q3 2017.

Goldentree Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2017 after selling out during the quarter.
Goldentree Asset Management sold 70,415 State Street SPDR S&P Biotech ETF shares in Q3 2017, an estimated $5.43M.
Goldentree Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 3 quarters.
Goldentree Asset Management's State Street SPDR S&P Biotech ETF position peaked at $14.8M in Q4 2016.
349 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2017.

Based on Goldentree Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.